1). Jamet D., Marzin Y., Douet-Guilbert N, et al. Jumping translocations in multiple myeloma. Cancer Genet Cytogenet. 2005. 161:159–63.
Article
2). Fan YS., Rizkalla K., William BF., Engel CJ. Jumping translocations of 11q in acute myeloid leukemia and 1q in follicular lymphoma. Cancer Genet Cytogenet. 2000. 118:35–41.
Article
3). Haltrich I., Kost-Alimova M., Kovacs G, et al. Jumping translocation of 17q11 approximately qter and 3q25 approximately q28 duplication in a variant Philadelphia t(9;14;22)(q34;q32;q11) in a childhood chronic myelogenous leukemia. Cancer Genet Cytogenet. 2006. 164:74–80.
4). Verdiman JW., Brunning RD., Harris NL, et al. Chronic myeloproliferative disease. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours: Tumours of haematopoietic and lymphoid tissues. Lyon, France: IARS Press;2001. p. 17–44.
5). Baxter EJ., Scott LM., Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorder. Lancet. 2005. 365:1054–61.
6). Han JY., Theil KS., Hoeltge G. Frequencies and characterization of cytogenetically unrelated clones in various hematologic malignancies: seven years of experiences in a single institution. Cancer Genet Cytogenet. 2006. 164:128–32.
Article
7). Andrieux J., Demory JL., Morel P, et al. Frequency of structural abnormalities of the long arm of chromosome 12 in myelofibrosis with myeloid metaplasia. Cancer Genet Cytogenet. 2002. 137:68–71.
Article
8). Nunoda K., Sashida G., Ohyashiki K., Kodama A., Fu-kutake K. The translocation (4;12)(q31;q21) in myelofibrosis associated with myelodysplastic syndrome: impact of the 12q21 breakpoint. Cancer Genet Cytogenet. 2006. 164:90–1.
Article
9). Reilly JT., Snowden JA., Spearing RL, et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol. 1997. 98:96–102.
Article
10). Przepiorka D., Bryant E., Kidd P. Idiopathic myelofibrosis in blast transformation with 4;12 and 5;12 translocation and a 7q deletion. Cancer Genet Cytogenet. 1988. 30:139–44.
11). Borrego S., Antinolo G., Martin-Noya A., Parody R. Translocation (8;12) in a patient with agnogenic myeloid metaplasia. Cancer Genet Cytogenet. 1993. 71:183–4.
Article
12). Miller JB., Testa JR., Lindgren V., Rowley JD. The pattern and clinical significance of karyotypic abnormalities in patients with idiopathic and postpoly-cythemic myelofibrosis. Cancer. 1985. 55:582–91.
Article
13). Sandberg AA., Morgan R., Betz J., Hashimi M., Vye MV. Unusual and unrelated polyclonality in a case of myeloid disease. Cancer Genet Cytogenet. 1996. 87:156–60.
Article
14). Tefferi A., Meyer RG., Wyatt WA., Dewald GW. Comparison of peripheral blood interphase cytogenetics with bone marrow karyotype analysis in myelofi brosis with myeloid metaplasia. Br J Haematol. 2001. 115:316–9.
15). Andrieux J., Demory JL., Dupriez B, et al. Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia. Genes Chromosomes Cancer. 2004. 39:82–7.